Literature DB >> 11135268

Benign conditions associated with raised serum CA-125 concentration.

P Buamah1.   

Abstract

A retrospective audit carried out in the Department of Clinical Biochemistry, covering a period of 42 months, showed 19 benign conditions, that gave rise to elevated serum CA-125 concentrations. These included six patients with non-malignant gynaecological disease, six patients with abdominal disorders, and seven patients with lung disease. These observations confirm that false-positive elevations can occur and that care must be taken before attributing an elevated serum CA-125 as an indicator of ovarian malignancy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11135268     DOI: 10.1002/1096-9098(200012)75:4<264::aid-jso7>3.0.co;2-q

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  41 in total

1.  Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.

Authors:  Richard G Moore; Michael Craig Miller; Elizabeth E Eklund; Karen H Lu; Robert C Bast; Geralyn Lambert-Messerlian
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

2.  Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia.

Authors:  Umran Kucukgoz Gulec; Semra Paydas; Ahmet Baris Guzel; Selim Buyukkurt; Gulsah Seydaoglu; Mehmet Ali Vardar
Journal:  Med Oncol       Date:  2012-01-25       Impact factor: 3.064

3.  Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.

Authors:  Richard G Moore; Michael Craig Miller; Margaret M Steinhoff; Steven J Skates; Karen H Lu; Geralyn Lambert-Messerlian; Robert C Bast
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

Review 4.  Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.

Authors:  Lara Paracchini; Maurizio D'Incalci; Sergio Marchini
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

Review 5.  Methylation and ovarian cancer: Can DNA methylation be of diagnostic use?

Authors:  Julie L Hentze; Claus K Høgdall; Estrid V Høgdall
Journal:  Mol Clin Oncol       Date:  2019-01-11

6.  The role of CA125 in clinical practice.

Authors:  E L Moss; J Hollingworth; T M Reynolds
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

7.  A Missed Diagnosis of Ovarian Torsion in a Patient with Bilateral Ovarian Dermoid Cysts: A Case Report.

Authors:  Agrima Ghosh; Rebecca McKay
Journal:  Cureus       Date:  2019-10-22

Review 8.  Role of biomarkers for early detection of ovarian cancer recurrence.

Authors:  Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco
Journal:  Gland Surg       Date:  2020-08

9.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

Authors:  Shuai Zhen; Li-Hong Bian; Li-Li Chang; Xin Gao
Journal:  Mol Clin Oncol       Date:  2014-04-16

10.  Ca-125: a useful marker to distinguish pulmonary tuberculosis from other pulmonary infections.

Authors:  J Fortún; P Martín-Dávila; R Méndez; A Martínez; F Norman; J Rubi; E Pallares; E Gómez-Mampaso; S Moreno
Journal:  Open Respir Med J       Date:  2009-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.